Imaging and Biomarkers of Hypoxia in Solid Tumors
| Status: | Terminated |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 11/8/2017 |
| Start Date: | December 2010 |
| End Date: | August 21, 2015 |
Hypoxia, meaning a lack of oxygen, has been associated strongly with a wide range of human
cancers. Hypoxia occurs when tumor growth exceeds the ability of blood vessels to supply the
tumor with oxygenated blood. It is currently understood that hypoxic tumors are more
aggressive. Current methods for measuring hypoxia include invasive procedures such as tissue
biopsy, or insertion of an electrode into the tumor. EF5-PET may be a non-invasive way to
measure tumor hypoxia.
cancers. Hypoxia occurs when tumor growth exceeds the ability of blood vessels to supply the
tumor with oxygenated blood. It is currently understood that hypoxic tumors are more
aggressive. Current methods for measuring hypoxia include invasive procedures such as tissue
biopsy, or insertion of an electrode into the tumor. EF5-PET may be a non-invasive way to
measure tumor hypoxia.
To establish PET imaging with the tracer EF5 as an accurate and reliable method for measuring
the oxygen content of a tumor and to establish the measurement of secreted markers in blood
as an accurate and reliable method for measuring the oxygen content of a tumor.
the oxygen content of a tumor and to establish the measurement of secreted markers in blood
as an accurate and reliable method for measuring the oxygen content of a tumor.
INCLUSION CRITERIA
- Any solid tumor malignancies of any stage meeting all of the following criteria:
Minimum tumor dimension is at least 1 cm (to ensure it is above the detection
threshold of PET imaging). Examples include but are not limited to: locally advanced
squamous cell carcinoma of the head and neck to be treated by either initial surgery
or primary chemoradiotherapy; inoperable non-small cell lung cancer or pancreatic
carcinoma to be treated with stereotactic radiotherapy, which may be biopsied again at
the time of percutaneous needle delivery of implanted fiducial markers.
- Patients with newly diagnosed malignancies should not have initiated treatment for
their disease before participating in this study. Patients with recurrent or second
malignancies may have had prior therapy as appropriate for their disease, but should
have completed all prior treatment at least 30 days before participation in this study
and should not have initiated new treatment for the current problem.
- Greater than or equal to eighteen years of age.
- Sufficiently healthy to tolerate all study procedures.
- Organ and marrow function sufficient to undergo planned therapy.
- Ability to understand and the willingness to sign a written informed consent document.
EXCLUSION CRITERIA
• Pregnant or nursing
We found this trial at
1
site
Stanford University School of Medicine Vast in both its physical scale and its impact on...
Click here to add this to my saved trials
